TALVEY (talquetamab-tgvs) injection

Talvey (talquetamab-tgvs) is a prescription drug that’s used to treat certain types of multiple myeloma. Brand Name: TALVEY (talquetamab-tgvs) injection, for subcutaneous use Initial U.S. Approval: 2023 

Home | talquetamab-tgvs injection

TALVEY, Buy TALVEY, TALVEY Price India, talquetamab, Buy talquetamab, talquetamab price india
TALVEY (talquetamab-tgvs) injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

TALVEY (talquetamab-tgvs) injection

Talquetamab-tgvs is used to treat multiple myeloma (a type of cancer of the bone marrow) that has returned or that did not respond to at least 4 other treatments. Talquetamab-tgvs is in a class of medications called bispecific T-cell engager antibodies. It works by killing cancer cells.

TALVEY is a bispecific GPRC5D-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

Talquetamab, sold under the brand name Talvey, is a humanized monoclonal antibody used for the treatment of multiple myeloma. It is a bispecific GPRC5D-directed CD3 T-cell engager. Talquetamab is a bispecific antibody against two targets: human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen with potential antineoplastic activity. Talquetamab binds both targets, drawing the T cells close to the tumor cells, causing a cytotoxic T-lymphocyte response.

Talquetamab was approved for medical use in both the United States and the European Union in August 2023. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Drug (Brand / Generic): TALVEY /talquetamab-tgvs
Current Indication: multiple myeloma
Approval Date: 2023

• 3 mg/1.5 mL (2 mg/mL) in a single-dose vial 
• 40 mg/mL in a single-dose vial 

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.